AnPac Bio-Medical Science Co. Ltd. (ANPC)
| Market Cap | 21.32M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 17.77M |
| EPS (ttm) | -1.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 227,564 |
| Open | 1.30 |
| Previous Close | 1.29 |
| Day's Range | 1.15 - 1.41 |
| 52-Week Range | 1.15 - 12.09 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ANPC
AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China. It offers cancer differentiation analysis devices and physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.
News
AnPac Bio Reports Nine Months Ended September 30, 2021, Same Period Achieved Record Revenue Increased By 55.3% While ...
PHILADELPHIA, Nov. 26, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United S...
CORRECTION -- Anpac Bio, USA
PHILADELPHIA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- In its press release dated November 9, 2021 entitled “AnPac Bio Announces Pricing of Approximately $2.9 Million Underwritten Public Offering of American D...
AnPac Bio Announces Pricing of Approximately $2.9 Million Underwritten Public Offering of American Depositary Shares
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC, the “Company”), a biotechnology company with operations in China and the United States focusing on earl...
UPDATE - AnPac Bio Commences Proposed Public Offering of American Depositary Shares
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC, the “Company”), a biotechnology company with operations in China and the United States focusing on earl...
AnPac Bio Commences Proposed Public Offering of American Depositary Shares
SUNRISE, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC, the “Company”), a biotechnology company with operations in China and the United States focusing on ear...
Anpac Bio Invites You to Join Us at the Q4 Virtual Investor Summit
Philadelphia, Pennsylvania--(Newsfile Corp. - November 8, 2021) - Anpac Bio (NASDAQ: ANPC) today announced that Phil Case, Head of Investor Relations | PR will be attending the Q4 Virtual Investor Summi...
AnPac Bio Study Shows Strong Correlation between CDA Score and Risk of Cancer and Diseases
Large Population Screening Study Reached Key Milestone with Over 2,000 Confirmed Cases Large Population Screening Study Reached Key Milestone with Over 2,000 Confirmed Cases
AnPac Bio 2021 First Half Revenue Up 128.5% with Non-GAAP Loss Reduced by 18.3%
PHILADELPHIA, Oct. 01, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United S...
AnPac Bio Receives NASDAQ Notification Regarding Minimum Market Value of Listed Securities Deficiency
PHILADELPHIA, Sept. 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and...
BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Ownership Increase In Subsidiary Holding
AnPac Bio-Medical Science (NASDAQ: ANPC) subsidiary AnPac Bio-Medical Science (Lishui) Co. Ltd. has increased its holding in AnPai (Shanghai) Healthcare Management Consultant Co. Ltd.
AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60%
PHILADELPHIA, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and...
AnPac Bio's USA Laboratory Receives Accreditation from the College of American Pathologists
PHILADELPHIA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and ...
AnPac Bio Successfully Completes Major PreClinical Study, Files with National Medical Products Administration (NMPA) ...
PHILADELPHIA, Aug. 23, 2021 (GLOBE NEWSWIRE) -- via Investor Wire – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in th...
AnPac Bio Taps Life Sciences and Diagnostics Veteran as US CEO
PHILADELPHIA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in Ch...
AnPac Bio and Roche Pharmaceuticals China Entered into Cooperation to Explore Innovative Healthcare and Medical Solut...
PHILADELPHIA, Aug. 05, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United S...
AnPac Bio Announces Appointment of New Independent Director
Independent Director has Strong Track Record at US Fortune 500 Companies Independent Director has Strong Track Record at US Fortune 500 Companies
AnPac Bio Began Generating Contract Medical Device R&D Revenue
Also in Final Stages of Partnership/Cooperation Discussions with Major Corporations Also in Final Stages of Partnership/Cooperation Discussions with Major Corporations
AnPac Bio Stock Gains On Robust Growth In Commercial Testing Volume In Q2
AnPac Bio-Medical Science Co Ltd (NASDAQ: ANPC) has announced strong growth in test volume in 1H of 2021. The total number of paid customers and testing volume increased almost 110% compared with 1H of ...
AnPac Bio Pre-announces that During First Half 2021, Total Commercial Testing Volume Increased Approximately 110% Ove...
PHILADELPHIA, July 20, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United S...
AnPac Bio-Medical Stock Moves Higher On First Disease Treatment US Patent
AnPac Bio-Medical Science Co Ltd (NASDAQ: ANPC) has received its first disease treatment patent by the United States Patent and Trademark Office. The patent covers novel medical devices for both disease...
Best Biotech Penny Stocks to Buy Next Month? 3 For Your Watchlist
Are these biotech penny stocks to watch on your list for July 2021? The post Best Biotech Penny Stocks to Buy Next Month?
AnPac Bio's First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds
PHILADELPHIA, June 18, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United S...
AnPac Bio Reports Strong First Quarter in 2021, with 137.2% Increase in Revenue and Record Number of Commercial Tests...
PHILADELPHIA, May 27, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United St...
AnPac Bio Shares Jump on Cancer Treatment Technology Related Joint Venture
AnPac Bio-Medical Science Co Ltd (NASDAQ: ANPC) will establish a joint venture with its founder and chairman, Dr. Chris Chang Yu, and certain other individuals to develop a new cancer treatment technolo...
AnPac Bio Launches Novel Cancer Treatment Technology and Product Joint Venture - Utilizing Findings from 10 Years of ...
SAN JOSE, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (ANPC) (“AnPac Bio,” the “Company” or “we”), a biotechnology company with operations in China and the United States...